Associations between misfolded alpha‐synuclein aggregates and Alzheimer's disease pathology in vivo is a dataset published in Alzheimer s & Dementia (2024). On theSindex it has a DataRank of 0.766, placing it in the top 26.3% of the data-sharing corpus. It has been cited 23 times, with 22 citing works in its 1-hop citation network.
Ranks in the top 26% for downstream scientific impact
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.477
From this paper's citation signal
Citation Network Contribution
0.289
From 15 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 22 citers.
H2020 European Research Council
Grant: ADG‐101096455
Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University, Swedish Alzheimer Foundation
Grant: AF-939981
Cure Alzheimer's fund
Grant: WASP/DDLS22-066
ERA PerMed
Grant: ERAPERMED2021-184
GHR Foundation, Swedish Research Council
Grant: 2022-00775
Knut and Alice Wallenberg foundation
Grant: 2022-0231
Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University, Swedish Alzheimer Foundation
Grant: AF-980907
NIA NIH HHS
Grant: U01 AG024904
Skåne University Hospital Foundation
Grant: 2020-O000028
Rönström Family Foundation
Grant: FRS-0003
NIA NIH HHS
Grant: R01 AG083740
EU Joint Programme Neurodegenerative Diseases
Grant: 2019-03401
European Research Council
Grant: ADG-101096455
Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University, Swedish Alzheimer Foundation
Grant: AF-980832
Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University, Swedish Alzheimer Foundation
Grant: AF-993465
Parkinson foundation of Sweden
Grant: 1412/22
GHR Foundation, Swedish Research Council
Grant: 2021-02219
Fonds de Recherche en Santé Québec
Grant: 298314
GHR Foundation, Swedish Research Council
Grant: 2018-02052
Regionalt Forskningsstöd
Grant: 2022-1259
European Commission
Grant: 825664
ERA-NET to support the Joint Programming in Neurodegenerative Diseases strategic plan (JPND)
European Commission
Grant: 101096455
Novel biomarkers for improving diagnostics, prognostics, and treatments of Alzheimer’s disease
National Institutes of Health
Grant: 1U01AG024904-01
Alzheimers Disease Neuroimaging Initiative
Canadian Institutes of Health Research
Grant: unidentified
unidentified
National Institutes of Health
Grant: 5R01AG083740-02
Prospective validation and implementation of high-performing blood biomarkers and digital cognitive tests for detection of Alzheimer's disease in specialist memory clinic and primary care settings
Alzheimer's Association
Alzheimer's Drug Discovery Foundation
BioClinica
Merck
BioClinica, Inc.
GE Healthcare
Janssen Alzheimer Immunotherapy Research & Development
Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
NIBIB NIH HHS
National Institutes of Health
Neurotrack Technologies
Pfizer Inc.
Alzheimer's Disease Neuroimaging Initiative
Eli Lilly and Company; EuroImmun
Fujirebio
LLC
NIH HHS
Swedish Brain Foundation
Eisai Inc.
Fujirebio Europe
Hjärnfonden
Lumosity; Lundbeck
National Institute of Biomedical Imaging and Bioengineering
Alzheimer's Drug Discovery Foundation
CereSpir, Inc.
Italian Ministero della Salute
Novartis Pharmaceuticals Corporation
Swedish federal government under the ALF agreement
Alzheimer's Disease Neuroimaging Initiative
Biogen; BristolMyers Squibb Company
Elan Pharmaceuticals, Inc.
F. Hoffmann-LaRoche Ltdand its affiliated company Genentech, Inc.
IXICO Ltd.
Merck & Co., Inc.
NeuroRxResearch
Piramal Imaging
Cogstate
Johnson & Johnson Pharmaceutical Research & Development LLC
MesoScale Diagnostics
National Institute on Aging
Pfizer
Alzheimer's Association
Araclon Biotech
Takeda Pharmaceutical Company; and Transition Therapeutics
FWCI
6.27
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals